Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03838926 · ClinicalTrials.gov registry record · Phase 1
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 1 study of Relapsed or Refractory Hematologic Malignancies, sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 11
- Study locations
NCT03838926 is a Phase 1 study of Relapsed or Refractory Hematologic Malignancies that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 42 participants. The trial reports 11 study locations across 5 states.
The verdict
NCT03838926, a Phase 1 study of Relapsed or Refractory Hematologic Malignancies, is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 11
- Study locations
Study Summary
The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Conditions Studied
Interventions
- DRUG Trichostatin A
Study Locations (11)
Other
- Vanda Investigational Site - Biała Podlaska
- Vanda Investigational Site - Katowice
- Vanda Investigational Site - Krakow
- Vanda Investigational Site - Opole
- Vanda Investigational Site - Skorzewo
- Vanda Investigational Site - Warsaw
- Vanda Investigational Site - Wroclaw
District of Columbia
- Vanda Investigational Site - Washington D.C.
Indiana
- Vanda Investigational Site - Lafayette
New Jersey
- Vanda Investigational Site - Hackensack
Washington
- Vanda Investigational Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03838926
The ClinicalTrials.gov registry entry for NCT03838926 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Trichostatin A is the first listed.
NCT03838926 reports 11 study locations spanning 5 distinct geographic areas - top geographies include Other, District of Columbia, Indiana.
Frequently Asked Questions
What is clinical trial NCT03838926 about?
NCT03838926 is a clinical study titled "Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies". The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
What is the current status of trial NCT03838926?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-09-27. Estimated completion is 2027-12.
What conditions does trial NCT03838926 study?
This clinical trial studies the following conditions: Relapsed or Refractory Hematologic Malignancies.
What interventions are being tested in trial NCT03838926?
The interventions under investigation include: Trichostatin A (DRUG).
Who is sponsoring clinical trial NCT03838926?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03838926 being conducted?
This trial has 11 study locations across District of Columbia, Indiana, New Jersey, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.